Celera sells Animal Genomics and Genotyping Business to Metamorhix, Inc.

08-Mar-2002

ROCKVILLE, MD and SAVAGE, MD, 2002--Celera genomics, an Applera Corporation business, and privately held MetaMorphix, Inc. (MMI), today announced the closing of the sale of Celera’s AgGen animal genomics and genotyping business to MetaMorphix. In addition, MetaMorphix has received a subscription to the Celera Discovery SystemTM. MetaMorphix intends to commercialize new products derived from Celera’s livestock genomic databases. In consideration, Celera has acquired a minority interest in MetaMorphix and is entitled to share future revenue generated from products developed by MetaMorphix based on Celera’s livestock databases. Other details of the agreements were not disclosed.

“We believe this transaction with MetaMorphix is an ideal way to leverage

value from the livestock genomics databases that Celera has generated, while allowing us to continue to focus our internal resources on activities related to our online and human therapeutics businesses,” said Tony L. White, Chairman of the Board and Chief Executive Officer, Applera Corporation and acting President, Celera Genomics.

“The creation of livestock genomic databases represents a quantum leap in

the development of new products for the animal health and livestock production industries. It is as historic to these industries as similar developments in the human health industry,” said Ed Quattlebaum, Ph.D., MetaMorphix Inc.’s Chairman, CEO and President.

“This acquisition will significantly enhance MetaMorphix's capabilities in

livestock genomics research,” continued Dr. Quattlebaum. “We are excited to have a team of Celera employees joining our company and strongly believe that this revolutionary technology will have a dramatic impact on modern day agronomics. This deal will significantly aid us in becoming a leading player in animal-based agricultural genomics.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances